Separation of Morphine and Metabolites Extracted from Blood Plasma

Application Note
Forensic Toxicology
Robert Ricker

Detection and quantitation of morphine and its metabolites in blood is important for forensic applications.

---

**Highlights**

- Good resolution and peak shape for morphine and two metabolites using ZORBAX SB-C18 at moderate pH.

- Electrochemical detection sensitively detects morphine and the metabolite morphine-6-glucuronide; while fluorescence allows sensitive detection of morphine-3-glucuronide.

---

**Conditions:**
ZORBAX SB-C18 (3.5µm; 4.6 x 150 mm) (Agilent P/N: 883953-902)
Mobile Phase: (97 : 3) 70mM KH₂PO₄ + 1mM EDTA : ACN, pH 4.5
Injection volume 50µL, 1.5 mL/min

---

A) electrochemical detect. (BAS Unijet) 720 mV
B) fluorescence detect. (Waters 470) exc. = 285 nm, em. = 352 nm

Courtesy of J. Visser, Center for Pharmacy, University of Groningen, The Netherlands
SAMPLE PREPARATION

1. Blood plasma (0.5 mL) is mixed with 0.1 ml internal standard, 0.5 mL H\textsubscript{2}O, 1 mL of 0.2M borate buffer pH 9, and 0.2 mL of 0.1M pentane-1-sulphonate. After each addition, the mix should be vortexed. The pentane-1-sulphonate solution must be prepared fresh weekly.

2. A solid phase C18 cartridge is activated with 3 x 1 mL MeOH followed by 3 x 1 mL H\textsubscript{2}O. The mixture above is then added to the cartridge and flushed with 3 x 1 mL H\textsubscript{2}O. Elution follows with 1 mL MeOH. This fraction is dried under nitrogen at 60° C, dissolved in 200µL of solvent, and vortexed. 50µL is injected onto the column.

Robert Ricker is an application chemist based at Agilent Technologies, Wilmington, Delaware.

For more information on our products and services, visit our website at:
www.agilent.com/chem

Copyright© 2002 Agilent Technologies, Inc. All Rights Reserved. Reproduction, adaptation or translation without prior written permission is prohibited, except as allowed under the copyright laws.

For Forensic Use only.

Information is subject to change without notice.

Printed in the USA
April 25, 2002
5988-6381EN